United Therapeutics Corporation Reports Third Quarter 2016 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/9/2026
- S&P 500 falls as AI worries hit software makers
- Brent crude hits six-week high near $97 as Houthi strike targets Saudi Aramco
- Qualcomm stock surges 9.5% on Amazon AI deal & 25M share warrant
- Energy stocks rise premarket as oil prices climb on Middle East supply fears
- Novartis shares plunge 10% as failed drug trial clouds growth outlook
- Harry and Meghan surprised by King Charles' letter on their status
- Citi initiates UiPath coverage with Buy rating and $23 target
- S&P 500 falls as AI worries hit software makers
- WestPark Capital Starts Akebia Therapeutics (AKBA) at Buy
- After an 18% summer selloff in chip stocks, Citi asks what comes next
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
Ladenburg Thalmann Upgrades United Therapeutics Corp. (UTHR) to Buy
October 28, 2016 7:43 AM EDTLadenburg Thalmann upgraded United Therapeutics Corp. (NASDAQ: UTHR) from Neutral to Buy with a price target of $138.00.
For an analyst ratings summary and ratings history on United Therapeutics Corp. click here. For more ratings news on United Therapeutics Corp. click here.
Shares of United Therapeutics Corp. closed at $116.34 yesterday.
... MoreUnited Therapeutics (UTHR) Tops Q3 EPS by 16c
October 27, 2016 7:59 AM EDTUnited Therapeutics (NASDAQ: UTHR) reported Q3 EPS of $3.50, $0.16 better than the analyst estimate of $3.34. Revenue for the quarter came in at $408.2 million versus the consensus estimate of $402.35 million.
For earnings history and earnings-related data on United Therapeutics (UTHR) click here.
... More